首页> 美国卫生研究院文献>OncoTargets and therapy >High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer
【2h】

High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer

机译:UBD的高表达与表柔比星耐药有关并表明三阴性乳腺癌的预后不良

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundTriple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is prone to recurrence and metastasis with worse prognosis. Epirubicin-based chemotherapy is of great importance for patients with TNBC, but resistance to epirubicin severely limits the application of this drug and this has emerged as a major problem in the treatment of TNBC. The ubiquitin protein D (UBD) molecule has often been considered a tumor oncogene, and has been shown to promote the recurrence and metastasis of malignant tumor cells. Since the role of UBD in epirubicin resistance and its prognostic value in TNBC have not been reported, the study reported here was designed to identify the epirubicin-resistance molecule and clarify the related biomarker for TNBC prognosis.
机译:背景三阴性乳腺癌(TNBC)是一种异质性乳腺癌亚型,易于复发和转移,预后较差。基于表柔比星的化学疗法对于TNBC患者非常重要,但是对表柔比星的耐药性严重限制了该药物的应用,这已成为治疗TNBC的主要问题。泛素蛋白D(UBD)分子通常被认为是肿瘤致癌基因,并已显示出可促进恶性肿瘤细胞的复发和转移。由于尚未报道UBD在表柔比星耐药中的作用及其在TNBC中的预后价值,因此本文报道的研究旨在鉴定表柔比星耐药分子并阐明TNBC预后的相关生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号